

Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Oct 21 2021, 8:30 AM EDT

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

Oct 13 2021, 8:30 AM EDT

SCYNEXIS Announces Preclinical Data at the 10th Trends in Medical Mycology Meeting Supporting Potential of Ibrexafungerp to Treat Mucormycosis

Oct 11 2021, 8:30 AM EDT

Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

LifeSci Advisors
Irina Koffler
T: 646-970-4681
ikoffler@lifesciadvisors.com

Leadership

Marco Taglietti, M.D.

President and Chief Executive Officer

David Angulo, M.D.

Chief Medical Officer

Eric Francois

Chief Financial Officer

Scott Sukenick

General Counsel

Christine Coyne

Chief Commercial Officer

Nkechi Azie, M.D., FIDSA

Vice President, Clinical Development and Medical Affairs

Jim Maffezzoli

Vice President, Marketing and Sales

Rajeshwar Motheram, Ph.D.

Senior Vice President, Pharmaceutical Development and Supply Chain

Glen D. Park, PharmD, MSJ

Vice President, Regulatory Affairs & Quality Assurance

SCYNEXIS, Inc.

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.